WO2023125418A1 - Cristaux de sel d'acide benzènesulfonique et leur procédé de préparation - Google Patents
Cristaux de sel d'acide benzènesulfonique et leur procédé de préparation Download PDFInfo
- Publication number
- WO2023125418A1 WO2023125418A1 PCT/CN2022/141957 CN2022141957W WO2023125418A1 WO 2023125418 A1 WO2023125418 A1 WO 2023125418A1 CN 2022141957 W CN2022141957 W CN 2022141957W WO 2023125418 A1 WO2023125418 A1 WO 2023125418A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- crystalline form
- isopropanol
- solid
- purin
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000013078 crystal Substances 0.000 title abstract description 19
- 150000008107 benzenesulfonic acids Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 54
- 239000007787 solid Substances 0.000 claims description 34
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 33
- 239000012458 free base Substances 0.000 claims description 26
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- HDXDQPRPFRKGKZ-INIZCTEOSA-N 3-(3-fluorophenyl)-2-[(1s)-1-(7h-purin-6-ylamino)propyl]chromen-4-one Chemical compound C=1([C@@H](NC=2C=3NC=NC=3N=CN=2)CC)OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HDXDQPRPFRKGKZ-INIZCTEOSA-N 0.000 claims description 6
- 239000012296 anti-solvent Substances 0.000 claims description 6
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 6
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 229940077388 benzenesulfonate Drugs 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000002441 X-ray diffraction Methods 0.000 claims description 3
- 239000012065 filter cake Substances 0.000 claims description 3
- 229940126062 Compound A Drugs 0.000 claims description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 230000000704 physical effect Effects 0.000 abstract description 10
- 229940125436 dual inhibitor Drugs 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- -1 4H-chromen-4-one compound Chemical class 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002411 thermogravimetry Methods 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 108091007960 PI3Ks Proteins 0.000 description 5
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 5
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001907 polarising light microscopy Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- CBXWGGFGZDVPNV-UHFFFAOYSA-N so4-so4 Chemical compound OS(O)(=O)=O.OS(O)(=O)=O CBXWGGFGZDVPNV-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Definitions
- the present invention relates to the field of medicine, in particular to a PI3K ⁇ / ⁇ dual inhibitor compound (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl) Crystallization of besylate salt of 4H-chromen-4-one compound and process for its preparation.
- Phosphoinositide-3 kinases belong to a class of intracellular lipid kinases that phosphorylate the 3-hydroxyl of the inositol ring of phosphoinositide lipids (PI), thereby generating lipid second messengers. It has been reported in the art that targeted inhibitors of the phosphoinositide-3-kinase (PI3K) pathway can be used as immunomodulators.
- a major issue in the large-scale production of pharmaceutical compounds is that the active substance should have stable crystalline polymorphs to ensure consistent processing parameters and drug quality. If an unstable crystalline form is used, the crystalline polymorph may change during manufacturing and/or storage, leading to quality control issues and formulation irregularities. Such variations may affect the reproducibility of the manufacturing process, resulting in a final formulation that does not meet the high quality and stringent requirements for formulation of pharmaceutical compositions.
- any modification of the solid state of a pharmaceutical composition that improves its physical and chemical stability confers a significant advantage in stability relative to less stable forms of the same drug.
- it is crucial to develop stable production methods that consistently produce active substances The existence of multiple crystalline forms with similar solubility poses a difficult challenge in the large-scale manufacture of pharmaceutical compounds.
- polymorphism When a compound crystallizes from a solution or slurry, it can crystallize in different spatial lattice arrangements, a property known as "polymorphism.” Each crystal form is called a "polymorph”. Although polymorphs of a given substance have the same chemical composition, they can differ in one or more physical properties such as solubility, degree of dissociation, true density, dissolution, melting point, crystal shape, compaction behavior, flow properties and and/or differ from each other in terms of solid-state stability.
- polymorphic behavior of drugs can be of great importance in pharmacology. Differences in physical properties exhibited by polymorphs affect practical parameters such as storage stability, compressibility and density (important in formulation and product manufacturing) and dissolution rate (an important factor in determining bioavailability). Changes in chemical reactivity (e.g., differential oxidation, causing color to change more quickly when the dosage form is one polymorph than when the dosage form is another polymorph), mechanical changes (e.g., tablet discoloration after storage) Kinetically favorable polymorphs convert to thermodynamically more stable polymorphs) or both (e.g. tablets of one polymorph disintegrate more easily at high humidity) may lead to loss of stability difference. Additionally, the physical properties of the crystals may be important in processing.
- one polymorph may be more likely to form solvates, causing aggregation of the solid form and making solid handling more difficult.
- the particle shape and size distribution of one polymorph relative to another may differ, leading to increased challenges in filtering pharmaceutical actives to remove impurities.
- WO2014195888A1 patent document discloses (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromene-4-one compound, its structural formula It is formula I, and as a free base, it exhibits dual inhibitory functions of PI3K ⁇ / ⁇ .
- the invention provides a benzene compound of (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromene-4-one compound
- a crystalline form of sulfonate characterized in that the crystalline form shows 13.28°, 20.72°, 21.70°, 18.80°, 18.14°, 17.26°, 23.81°, 23.02°, 11.12°, Peaks at diffraction angles 2 ⁇ of 14.00°, 23.44°, 22.14° ( ⁇ 0.2°).
- the benzenesulfonate crystalline form also includes crystals at 27.25°, 28.31°, 22.43°, 26.47°, 34.51°, 28.84°, 20.32°, 16.52°, 27.97°, 27.251°, 26.91°, 33.14° , 31.07°, 24.96°, 8.94°, 29.31°, 29.65°, 32.60°, 31.32°, 38.81°, 33.51°, 37.77°, 37.09° ( ⁇ 0.2°) at the diffraction angle 2 ⁇ .
- the crystalline form of besylate salt shows an X-ray diffraction pattern substantially as shown in FIG. 5 .
- the present invention also provides a (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromene- Process for the preparation of crystalline forms of besylate salts of 4-keto compounds, characterized in that it comprises the following steps:
- Step (1) Weigh a certain mass of (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromene-4-
- the ketone free base compound is added to a certain volume of isopropanol solvent and dissolved in a water bath to obtain solution 1;
- Step (2) Weigh a certain mass of benzenesulfonic acid ligand, heat it ultrasonically and dissolve it in a certain volume of isopropanol to obtain solution 2;
- Step (3) adding the solution 2 obtained in step (2) dropwise to the stirred solution 1 obtained in step (1) to obtain solution 3;
- Step (4) Stir the solution 3 obtained in step (3), and no solid is precipitated, and a certain volume of anti-solvent is added to the solution to precipitate a solid, and the stirring is continued to obtain a suspension;
- Step (5) filter the suspension obtained in step (4) under reduced pressure, rinse the surface of the filter cake with isopropanol, and vacuum-dry the obtained solid at room temperature to obtain the crystalline form.
- the anti-solvent in step (4) is selected from n-heptane.
- the volume ratio of the volume of isopropanol in step (1), step (2) to the antisolvent in step (4) is 2:0.1-0.5:3.
- the molar ratio of the free base compound in step (1) to the benzenesulfonic acid ligand in step (2) is 1:1.5, preferably 1:1.1.
- Benzenesulfonate of (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromene-4-one compound of the present invention The crystals have good crystallinity, slightly hygroscopicity, controllable crystal form preparation, and exhibit excellent pharmacokinetics, and can be used as PI3K ⁇ / ⁇ inhibitors.
- the TGA figure of accompanying drawing 6 besylate crystal form
- the DSC figure of accompanying drawing 7 besylate crystal form
- the PLM figure of accompanying drawing 9 besylate crystal form
- the 1 HNMR figure of accompanying drawing 10 besylate crystal form
- the crystal form of the samples was analyzed by X-powder diffractometer.
- the 2 ⁇ scanning angle of the sample is from 3° to 40°, the scanning step is 0.02°, and the scanning time of each step is 0.2s.
- the light tube voltage and current were 40kV and 40mA, respectively.
- the samples were analyzed by TA instruments Q200 DSC. Put the weighed sample (0.5mg-5mg) into the sample tray, and raise the sample to the final temperature at a rate of 10°C/min under the protection of nitrogen (50mL/min).
- the samples were analyzed by TA instruments Q500.
- the sample was put into a tared platinum crucible, the system automatically weighed, and then the sample was raised to the final temperature at a rate of 10°C/min under the protection of nitrogen (40mL/min).
- the samples were analyzed using a polarizing microscope, and the morphology and microstructure of the crystals were obtained by adjusting different magnifications.
- Dynamic moisture adsorption was performed using TA Instruments Q5000 SA. Approximately 1-10 mg of sample is placed in a sample pan and suspended from the sample chamber. The room temperature was maintained at a constant 25 ⁇ 1°C by a water bath. In the step mode, the sample is subjected to a cycle test in the relative humidity of 0%RH-80%RH. Analysis was performed at 10% RH/step. Set the time to maintain each humidity to 90min, so that the sample and the indoor environment can reach equilibrium.
- the samples were analyzed using Bruker Ascend 500MH, and the solvent was deuterated dimethyl sulfoxide.
- Step (1) About 200 mg of the free base compound prepared in Example 2.1 was added to 2 mL of isopropanol, and dissolved in a water bath at 60 ° C to obtain solution 1;
- Step (2) about 94 mg of benzenesulfonic acid was dissolved in 0.4 mL of isopropanol by ultrasonic heating to obtain solution 2;
- Step (3) adding solution 2 dropwise to solution 1 under stirring to obtain solution 3;
- Step (4) The solution 3 was stirred for about 1 day without solid precipitation, and 3 mL of n-heptane was added to precipitate a solid, which turned into oil after stirring, and continued stirring for about 2 days to obtain a suspension.
- Step (5) The suspension was suction-filtered under reduced pressure, the surface of the filter cake was washed with isopropanol, and the obtained solid was vacuum-dried overnight at room temperature to obtain crystalline form 1 of besylate salt (about 200 mg).
- API represents the free base compound prepared in Example 2.1
- base represents the free base compound
- acid represents the benzenesulfonic acid pair ion ligand.
- Step (1) Weigh about 200 mg of the free base compound prepared in Example 2.1, add 2 mL of isopropanol, and dissolve in a water bath at 60°C to obtain solution 1;
- Step (2) about 103 mg of citric acid was dissolved in 0.8 mL of isopropanol to obtain solution 2;
- Step (3) adding solution 2 dropwise to solution 1 under stirring to obtain solution 3;
- Step (4) Solution 3 was stirred overnight without solid precipitation, and 3 mL of n-heptane was added to solution 3 to precipitate solid, which turned into oil after stirring;
- Step (5) The supernatant was discarded, and the obtained oil was vacuum-dried at room temperature overnight to obtain an amorphous solid of citrate, whose XRPD is shown in Figure 11 and 1 HNMR is shown in Figure 12 .
- Step (1) about 200mg of the free base compound prepared in Example 2.1, add 2mL of isopropanol, dissolve in a water bath at 60°C, solution 1;
- Step (2) about 73mg L-malic acid was dissolved in 0.8mL isopropanol to obtain solution 2;
- Step (3) adding solution 2 dropwise to solution 1 under stirring to obtain solution 3;
- Step (4) Solution 3 was stirred overnight without solid precipitation, and 3 mL of n-heptane was added to Solution 3, and oil was precipitated after stirring for about 2 days;
- Step (5) The supernatant was discarded, and the obtained oil was vacuum-dried overnight at room temperature to obtain an amorphous solid of L-malate, whose XRPD is shown in Figure 13 and 1 HNMR is shown in Figure 14 .
- Step (1) About 200 mg of the free base compound prepared in Example 2.1 was added to 2 mL of isopropanol, and dissolved in a water bath at 60°C to obtain solution 1;
- Step (2) About 55 mg of sulfuric acid was dissolved in 0.4 mL of isopropanol to obtain solution 2;
- Step (3) adding solution 2 dropwise to solution 1 under stirring to obtain solution 3;
- Step (4) Solids were precipitated from solution 3 immediately, dissolved after stirring for about 1 day, and 4 mL of n-heptane was added, solids were precipitated, and oil was formed after stirring for about 2 days;
- Step (5) The supernatant was discarded, and the obtained oil was vacuum-dried overnight at room temperature to obtain an amorphous sulfate sulfate solid, whose XRPD is shown in Figure 15 .
- Step (1) about 200mg of the free base compound prepared in Example 2.1, add 2mL of isopropanol, dissolve in a water bath at 60°C, solution 1;
- Step (2) about 80mg L-tartaric acid was dissolved in 0.8mL isopropanol to obtain solution 2;
- Step (3) adding solution 2 dropwise to solution 1 under stirring to obtain solution 3;
- Step (4) The solution 3 was slightly turbid, and a large amount of solids did not precipitate out after stirring overnight. Add 3mL of n-heptane, the solids precipitated, and stirred for about 2 days to form an oil;
- Step (5) The supernatant was discarded, and the obtained oil was vacuum-dried at room temperature overnight to obtain an amorphous solid of L-tartrate salt, whose XRPD is shown in Figure 16 and 1 HNMR is shown in Figure 17 .
- Step (1) About 200 mg of the free base compound prepared in Example 2.1 was added to 2 mL of isopropanol, and dissolved in a water bath at 60 ° C to obtain solution 1;
- Step (2) about 93 mg of p-toluenesulfonic acid was dissolved in 0.4 mL of isopropanol to obtain solution 2;
- Step (3) adding solution 2 dropwise to solution 1 under stirring to obtain solution 3;
- Step (4) Solution 3 was stirred for about 1 day without solid precipitation, added 3 mL of n-heptane, solid was precipitated, and stirred for about 2 days to form an oil;
- Step (5) The supernatant was discarded, and the obtained oil was vacuum-dried overnight at room temperature to obtain an amorphous solid of p-toluenesulfonate, whose XRPD is shown in Figure 18 and 1 HNMR is shown in Figure 19 .
- Step (1) About 200 mg of the free base compound prepared in Example 2.1 was added to 2 mL of isopropanol, and dissolved in a water bath at 60 ° C to obtain solution 1;
- Step (2) about 44 ⁇ L of hydrochloric acid was dissolved in 0.4 mL of isopropanol to obtain solution 2;
- Step (3) adding solution 2 dropwise to solution 1 under stirring to obtain solution 3;
- Step (4) Solution 3 was stirred for about 1 day without precipitation of solids, and 3 mL of n-heptane was added to precipitate solids, and stirred for about 2 days to form an oil;
- Step (5) The supernatant was discarded, and the obtained oil was vacuum-dried at room temperature overnight to obtain an amorphous hydrochloride solid, and its XRPD is shown in Figure 20.
- Step (1) About 200 mg of the free base compound prepared in Example 2.1 was added to 2 mL of isopropanol, and dissolved in a water bath at 60 ° C to obtain solution 1;
- Step (2) About 62 mg of maleic acid was dissolved in 0.4 mL of isopropanol to obtain solution 2;
- Step (3) adding solution 2 dropwise to solution 1 under stirring to obtain solution 3;
- Step (4) Solution 3 was stirred for about 1 day without solid precipitation, added 3 mL of n-heptane, solid was precipitated, and stirred for about 2 days to form an oil;
- Step (5) The supernatant was discarded, and the obtained oil was vacuum-dried overnight at room temperature to obtain an amorphous maleate salt, whose XRPD is shown in Figure 21 and 1 HNMR is shown in Figure 22 .
- Step (1) About 200 mg of the free base compound prepared in Example 2.1 was added to 2 mL of isopropanol, and dissolved in a water bath at 60 ° C to obtain solution 1;
- Step (2) about 53 mg of methanesulfonic acid was dissolved in 0.4 mL of isopropanol to obtain solution 2;
- Step (3) adding solution 2 dropwise to solution 1 under stirring to obtain solution 3;
- Step (4) Solution 3 was stirred for about 1 day without solid precipitation, added 3 mL of n-heptane, solid was precipitated, and stirred for about 2 days to form an oil;
- Step (5) The supernatant was discarded, and the obtained oil was vacuum-dried overnight at room temperature to obtain an amorphous solid of mesylate salt, whose XRPD is shown in Figure 23 and 1 HNMR is shown in Figure 24 .
- the present invention also studies (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one free base and benzene
- Animal blood collection points are before and after administration and 0.25, 0.5, 1, 2, 4, 8 and 24 hours.
- Jugular vein blood collection the blood collection volume of each blood collection point is about 150 ⁇ L, EDTA-K2 anticoagulant, within 15 minutes after sampling 4 Centrifuge at 2000g for 5min, and analyze by LCMSMS-28 (Triple Quad 6500+).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des cristaux d'un sel d'acide benzènesulfonique d'un composé (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophényl)-4H-chroméne-one composé inhibiteur double de PI3Kδ/γ et son procédé de préparation. Une forme cristalline selon la présente invention a d'excellentes propriétés physiques et pharmacodynamiques/pharmacocinétiques.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111679211.9 | 2021-12-31 | ||
CN202111679211 | 2021-12-31 | ||
CN202210245007.4 | 2022-03-11 | ||
CN202210245007.4A CN116410194A (zh) | 2021-12-31 | 2022-03-11 | 一种苯磺酸盐结晶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023125418A1 true WO2023125418A1 (fr) | 2023-07-06 |
Family
ID=86997809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/141957 WO2023125418A1 (fr) | 2021-12-31 | 2022-12-26 | Cristaux de sel d'acide benzènesulfonique et leur procédé de préparation |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202334154A (fr) |
WO (1) | WO2023125418A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105358560A (zh) * | 2013-06-07 | 2016-02-24 | 理森制药股份公司 | 双重选择性PI3δ和γ激酶抑制剂 |
CN106279170A (zh) * | 2015-05-12 | 2017-01-04 | 苏州晶云药物科技有限公司 | 5-氟-3-苯基-2-((1s)-1-(9h-嘌呤-6-基氨基)丙基)-3h-喹唑啉-4-酮的无水晶型及其制备方法 |
-
2022
- 2022-12-26 WO PCT/CN2022/141957 patent/WO2023125418A1/fr unknown
- 2022-12-30 TW TW111150924A patent/TW202334154A/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105358560A (zh) * | 2013-06-07 | 2016-02-24 | 理森制药股份公司 | 双重选择性PI3δ和γ激酶抑制剂 |
CN106279170A (zh) * | 2015-05-12 | 2017-01-04 | 苏州晶云药物科技有限公司 | 5-氟-3-苯基-2-((1s)-1-(9h-嘌呤-6-基氨基)丙基)-3h-喹唑啉-4-酮的无水晶型及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
TW202334154A (zh) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5289948B2 (ja) | 4−メチル−n−[3−(4−メチル−イミダゾール−1−イル)−5−トリフルオロメチル−フェニル]−3−(4−ピリジン−3−イル−ピリミジン−2−イルアミノ)−ベンズアミドの結晶形態 | |
JP5894153B2 (ja) | ニロチニブ塩及びそれらの結晶性形態 | |
JP6609065B2 (ja) | 1−(5−(2,4−ジフルオロフェニル)−1−((3−フルオロフェニル)スルホニル)−4−メトキシ−1h−ピロール−3−イル)−n−メチルメタンアミンの新規な酸付加塩 | |
TWI736570B (zh) | Egfr抑制劑游離鹼或其酸式鹽的多晶型、其製備方法和應用 | |
KR20120123532A (ko) | 4-[-2-[[5-메틸-1-(2-나프탈레닐)-1h-피라졸-3-일]옥시]에틸]모르폴린 염산염 결정다형 및 용매화물 | |
JP5899214B2 (ja) | 4−[−2−[[5−メチル−1−(2−ナフタレニル)−1h−ピラゾール−3−イル]オキシ]エチル]モルホリン塩酸塩の固体形態 | |
US20170313664A1 (en) | Novel form of pyrimidine compound having dibenzylamine structure | |
JP6816036B2 (ja) | ヒストン脱アセチル化阻害剤の結晶形態 | |
CN113840604A (zh) | Jak2抑制剂的结晶形式 | |
WO2011023146A1 (fr) | Polymorphes de mésylate d'imatinib générés par cristallisation dans des solutions salines inorganiques aqueuses | |
WO2020244612A1 (fr) | Polymorphe d'un inhibiteur de cdk9, procédé de préparation du polymorphe et utilisation associée | |
WO2023125418A1 (fr) | Cristaux de sel d'acide benzènesulfonique et leur procédé de préparation | |
WO2015003571A1 (fr) | Nouvelle forme cristalline de mésylate de dabrafenib et procédé de préparation de celle-ci | |
WO2023125419A1 (fr) | Cristal d'adipate et son procédé de préparation | |
WO2023123742A1 (fr) | CRISTAL SEMI-FUMARATE DE COMPOSÉ INHIBITEUR DOUBLE DE PI3Kδ/γ ET SON PROCÉDÉ DE PRÉPARATION | |
US10604521B2 (en) | Crystalline forms of PLX3397 hydrochloride, processes for preparation and use thereof | |
WO2017028802A1 (fr) | Forme cristalline de dichlorhydrate de 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluorométhyl)-2-pyridinamine et son procédé de préparation | |
CN116410194A (zh) | 一种苯磺酸盐结晶及其制备方法 | |
WO2018137670A1 (fr) | Forme cristalline du médicament inhibiteur de protéine virale (vx-287), et son procédé de préparation et d'utilisation | |
CN116410195A (zh) | 一种己二酸盐结晶及其制备方法 | |
WO2023078440A1 (fr) | Forme cristalline de sel de dérivé de pyrazine et son procédé de préparation | |
WO2022199707A1 (fr) | Sel pharmaceutiquement acceptable de pimavansérine, procédé de préparation associé, composition pharmaceutique la contenant et utilisation associée | |
JP2010518072A (ja) | 新規のイマチニブカンシラート及びその製造方法 | |
CN116410193A (zh) | PI3Kδ/γ双重抑制剂化合物的半富马酸盐结晶及其制备方法 | |
WO2017098336A1 (fr) | Nouveaux polymorphes de vemurafenib, leur procédé de préparation, et composition pharmaceutique les contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22914672 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |